Results 31 to 40 of about 3,610 (188)
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. [PDF]
We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest ...
Francesco Checchi +5 more
doaj +1 more source
Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis. [PDF]
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects ...
A. Meussen +10 more
core +2 more sources
Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei [PDF]
OBJECTIVES: The objective of this study was to identify the mechanisms of resistance to nifurtimox and fexinidazole in African trypanosomes. METHODS: Bloodstream-form Trypanosoma brucei were selected for resistance to nifurtimox and fexinidazole by ...
Berriman, Matthew +5 more
core +3 more sources
The fluorinated ornithine analog α-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.
Nicole LoGiudice +4 more
doaj +1 more source
Human African Trypanosomiasis (HAT) is caused by unicellular flagellated protozoan parasites of the genus Trypanosoma brucei. The subspecies T. b. gambiense is mainly responsible for mostly chronic anthroponotic infections in West- and Central Africa ...
Andrés Álvarez-Rodríguez +7 more
doaj +1 more source
Management of trypanosomiasis and leishmaniasis [PDF]
<p>Background: The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress ...
Alsford +39 more
core +2 more sources
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. [PDF]
Trypanosoma brucei gambiense is the main causative agent of Human African Trypanosomiasis (HAT), also known as sleeping sickness. Because of limited alternatives and treatment toxicities, new therapeutic options are urgently needed for patients with HAT.
Frédéric-Antoine Dauchy +8 more
doaj +1 more source
The development of drugs for treatment of sleeping sickness: a historical review
Only four drugs are available for the chemotherapy of human African trypanosomiasis or sleeping sickness; Suramin, pentamidine, melarsoprol and eflornithine. The history of the development of these drugs is well known and documented. suramin, pentamidine
Steverding Dietmar
doaj +1 more source
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women (4%–20%) when the ovaries create abnormally high levels of androgens, the male sex hormones that are typically present in women in trace amounts.
Tanzina Akter +8 more
doaj +1 more source
Characterisation and semi-mechanistic modelling of eflornithine pharmacokinetics and evalutation of prodrugs in oral treatment against late-stage human African trypanosomiasis [PDF]
The present thesis explores the hypothesis that treatment of human African trypanosomiasis can be improved by characterising the enantioselective pharmacokinetics of eflornithine, and investigating the oral eflornithine absorption.
Johansson, Carl
core +1 more source

